 |
 |
An online article published by SCO Financial Group, a financial analysis firm, describes how technologies being developed by ARIAD Pharmaceuticals, a biotech firm, might address two problems noted in connection with the fetal transplant trials. 1) Insufficient supplies of fetal tissue: ARIAD would use cultured stem cell lines to which differentiation controls are applied so as to produce the required neural tissue. 2) Runaway dyskinesias: The tissue generated for transplant would be engineered with a cell "suicide" gene that would be activated with a drug at the proper point so as to reign in cell proliferation. See the full article at http://www.smallcapsonline.com/mc_010308.php3. Phil Tompkins Amherst MA age 63/dx 1990 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn